Now showing items 1-6 of 6

    • Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints 

      Koyama, Shohei; Akbay, Esra A.; Li, Yvonne Y.; Herter-Sprie, Grit S.; Buczkowski, Kevin A.; Richards, William G.; Gandhi, Leena; Redig, Amanda J.; Rodig, Scott J.; Asahina, Hajime; Jones, Robert E.; Kulkarni, Meghana M.; Kuraguchi, Mari; Palakurthi, Sangeetha; Fecci, Peter E.; Johnson, Bruce E.; Janne, Pasi A.; Engelman, Jeffrey A.; Gangadharan, Sidharta P.; Costa, Daniel B.; Freeman, Gordon J.; Bueno, Raphael; Hodi, F. Stephen; Dranoff, Glenn; Wong, Kwok-Kin; Hammerman, Peter S. (Nature Publishing Group, 2016)
      Despite compelling antitumour activity of antibodies targeting the programmed death 1 (PD-1): programmed death ligand 1 (PD-L1) immune checkpoint in lung cancer, resistance to these therapies has increasingly been observed. ...
    • Chemotherapy for locally advanced and metastatic pulmonary carcinoid tumors 

      Chong, Curtis Robert; Wirth, Lori Julin; Nishino, Mizuki; Chen, Aileen Betty; Sholl, Lynette Marie; Kulke, Matthew H; McNamee, Ciaran; Janne, Pasi Antero; Johnson, Bruce Evan (Elsevier BV, 2014)
      Objectives The optimal management of locally advanced and metastatic pulmonary carcinoid tumors remains to be determined. Materials and methods A retrospective review was conducted on patients with typical and ...
    • Clinical, Pathologic, and Biologic Features Associated with BRAF Mutations in Non-Small Cell Lung Cancer 

      Cardarella, S.; Ogino, Atsuko; Nishino, Michiya; Butaney, M.; Shen, Jeanne; Lydon, C.; Yeap, Beow Yong; Sholl, Lynette Marie; Johnson, Bruce Evan; Janne, Pasi Antero (American Association for Cancer Research (AACR), 2013)
      Purpose BRAF mutations are found in a subset of non-small cell lung cancers (NSCLCs). We examined the clinical characteristics and treatment outcomes of patients with NSCLC harboring BRAF mutations. Experimental ...
    • Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience 

      Sholl, Lynette Marie; Aisner, Dara L.; Varella-Garcia, Marileila; Berry, Lynne D.; Dias-Santagata, Dora; Wistuba, Ignacio I.; Chen, Heidi; Fujimoto, Junya; Kugler, Kelly; Franklin, Wilbur A.; Iafrate, Anthony John; Ladanyi, Marc; Kris, Mark G.; Johnson, Bruce Evan; Bunn, Paul A.; Minna, John D.; Kwiatkowski, David Joseph (Elsevier BV, 2015)
      Introduction Molecular genetic analyses of lung adenocarcinoma have recently become standard of care for treatment selection. The Lung Cancer Mutation Consortium was formed to enable collaborative multi-institutional ...
    • A Phase I trial of high dose gefitinib for patients with leptomeningeal metastases from non-small cell lung cancer 

      Jackman, David M.; Cioffredi, Leigh A.; Jacobs, Lorraine; Sharmeen, Farhana; Morse, Linda K.; Lucca, Joan; Plotkin, Scott R.; Marcoux, Paul J.; Rabin, Michael S.; Lynch, Thomas J.; Johnson, Bruce E.; Kesari, Santosh (Impact Journals LLC, 2015)
      Introduction: There are few effective treatment options for leptomeningeal metastasis (LM) in non-small-cell lung cancer (NSCLC). This study assessed the feasibility of high-dose gefitinib in patients with LM from NSCLC ...
    • Tumoral cavitation in patients with non-small-cell lung cancer treated with antiangiogenic therapy using bevacizumab 

      Nishinoa, Mizuki; Cryer, Sarah K.; Okajim, Yuka; Sholl, Lynette Marie; Hatabu, Hiroto; Rabin, Michael Seth; Jackman, David M; Johnson, Bruce Evan (E-MED LTD, 2012)
      Rationale and objectives: To investigate the frequency and radiographic patterns of tumoral cavitation in patients with non-small cell lung cancer (NSCLC) treated with bevacizumab, and correlate the imaging findings with ...